Aurinia Pharmaceuticals Inc. (AUPH) Financials

$8.38

south_east
-$0.16 (-1.87%)
Day's range
$8.33
Day's range
$8.68

AUPH Income statement / Annual

Last year (2024), Aurinia Pharmaceuticals Inc.'s total revenue was $235.13 M, an increase of 33.97% from the previous year. In 2024, Aurinia Pharmaceuticals Inc.'s net income was $5.75 M. See Aurinia Pharmaceuticals Inc.,s key income statements, including revenue, expenses, profit, and income.

Period FY-2024 FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015
Period Ended 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Operating Revenue $235.13 M $175.51 M $134.03 M $45.61 M $50.12 M $318,000.00 $463,000.00 $420,000.00 $173,000.00 $235,000.00
Cost of Revenue $28.25 M $14.15 M $5.66 M $1.09 M $50.33 M $52.87 M $41.38 M $1,000.00 $4,000.00 $12,000.00
Gross Profit $206.89 M $161.37 M $128.37 M $44.51 M -$209,000.00 -$52.55 M -$40.92 M $419,000.00 $169,000.00 $223,000.00
Gross Profit Ratio 0.88 0.92 0.96 0.98 -0 -165.25 -88.38 1 0.98 0.95
Research and Development Expenses $20.79 M $49.64 M $44.99 M $51.14 M $50.33 M $52.87 M $41.38 M $33.93 M $14.53 M $15.98 M
General & Administrative Expenses $157.93 M $195.04 M $196.37 M $171.44 M $95.98 M $22.15 M $13.67 M $12.10 M $6.97 M $6.26 M
Selling & Marketing Expenses $14.09 M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Selling, General & Administrative Expenses $172.03 M $195.04 M $196.37 M $171.44 M $95.98 M $22.15 M $13.67 M $12.10 M $6.97 M $6.26 M
Other Expenses $18.76 M $8.38 M -$1.52 M $2.67 M $1.29 M $1.55 M $2.07 M $195,000.00 -$1.63 M -$337,000.00
Operating Expenses $211.57 M $253.06 M $239.84 M $225.25 M $147.60 M $76.57 M $56.62 M $47.48 M $22.98 M $23.80 M
Cost And Expenses $239.82 M $267.20 M $245.50 M $226.34 M $147.60 M $76.57 M $56.62 M $47.48 M $22.99 M $23.82 M
Interest Income $16.97 M $17.00 M $5.12 M $529,000.00 $1.52 M $2.70 M $2.23 M $1.04 M $27,000.00 $50,000.00
Interest Expense $4.84 M $2.78 M $5.12 M $0.00 $0.00 $39,000.00 $2.23 M $702,000.00 $27,000.00 $50,000.00
Depreciation & Amortization $19.45 M $11.65 M $2.71 M $2.76 M $1.37 M $1.17 M $1.57 M $1.46 M $1.48 M $1.56 M
EBITDA $31.73 M -$63.05 M -$103.65 M -$177.45 M -$102.92 M -$89.77 M -$53.93 M -$45.61 M -$21.34 M -$22.02 M
EBITDA Ratio 0.13 -0.36 -0.83 -3.92 -1.92 -254.69 -96.41 -51.63 -120.39 -114.66
Operating Income Ratio -0.02 -0.52 -0.83 -3.96 -2.08 -259.56 -121.29 -112.05 -131.87 -100.34
Total Other Income/Expenses Net $12.14 M $14.22 M $5.12 M $529,000.00 $1.52 M $2.70 M $2.23 M -$23.73 M -$481,000.00 $4.97 M
Income Before Tax $7.45 M -$77.47 M -$106.35 M -$180.21 M -$102.77 M -$123.70 M -$64.05 M -$70.79 M -$23.30 M -$18.61 M
Income Before Tax Ratio 0.03 -0.44 -0.79 -3.95 -2.05 -389 -138.33 -168.55 -134.65 -79.18
Income Tax Expense $1.70 M $551,000.00 $1.83 M $760,000.00 -$94,000.00 $144,000.00 $73,000.00 $23.92 M $481,000.00 -$4.97 M
Net Income $5.75 M -$78.02 M -$108.18 M -$180.97 M -$102.68 M -$123.85 M -$64.12 M -$70.79 M -$23.30 M -$18.61 M
Net Income Ratio 0.02 -0.44 -0.81 -3.97 -2.05 -389.45 -138.49 -168.55 -134.65 -79.18
EPS 0.0402 -0.54 -0.76 -1.4 -0.87 -1.33 -0.76 -0.92 -0.66 -0.58
EPS Diluted 0.0393 -0.54 -0.76 -1.4 -0.87 -1.33 -0.76 -0.92 -0.66 -0.58
Weighted Average Shares Out $143.06 M $143.24 M $141.92 M $129.37 M $118.47 M $93.02 M $84.78 M $76.92 M $35.29 M $32.15 M
Weighted Average Shares Out Diluted $146.19 M $143.24 M $141.92 M $129.37 M $118.47 M $93.02 M $84.78 M $76.95 M $35.29 M $32.15 M
Link